MOTS-c FDA Approval History: Regulatory Status, Safety Data, and What Clinicians Need to Know

What Is MOTS-c and Why Does Its Regulatory History Matter?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a peptide encoded within mitochondrial DNA, not nuclear DNA. That origin makes it biologically novel. The regulatory history matters because MOTS-c is actively sold online, dispensed by some compounding pharmacies, and discussed in telehealth contexts, yet it carries no FDA-reviewed evidence of safety or efficacy in humans.

Discovery and Early Characterization

Lee et al. Published the foundational characterization of MOTS-c in Cell Metabolism in February 2015. That paper demonstrated that synthetic MOTS-c reduced obesity and improved insulin sensitivity in high-fat-diet mouse models, and it identified AMPK pathway activation as a central mechanism [1]. The peptide is 16 amino acids long with the sequence MRWQEMGYIFYPRKLR.

Endogenous MOTS-c circulates in human plasma. One cross-sectional study published in Aging (Albany NY) found that plasma MOTS-c levels decline with age and correlate inversely with markers of metabolic dysfunction [2]. That correlation is hypothesis-generating, not a clinical endpoint.

No IND, No NDA, No BLA

A search of Drugs@FDA returns zero results for "MOTS-c" as of January 2025. The FDA's drug approval pathway requires an Investigational New Drug (IND) application before human trials begin, followed by Phase 1 through Phase 3 data, a New Drug Application (NDA) or Biologics License Application (BLA), and agency review. MOTS-c has cleared none of those stages publicly. No sponsor has announced a filed IND, and no ClinicalTrials.gov registration lists an active MOTS-c interventional human trial as of this writing [3].

Current FDA Regulatory Classification of MOTS-c

The FDA has not formally classified MOTS-c under any product category with an approved pathway. That creates a practical vacuum that has been filled by the research-chemical and compounding markets.

Drug vs. Biologic vs. Dietary Supplement

MOTS-c does not meet the statutory definition of a dietary supplement under 21 U.S.C. § 321(ff) because it was not marketed as a supplement before the Dietary Supplement Health and Education Act (DSHEA) of 1994, and it is a synthetic peptide, not a vitamin, mineral, herb, or botanical. The FDA's guidance on new dietary ingredients requires a 75-day pre-market notification for new dietary ingredients; no such notification for MOTS-c appears in the FDA's public NDI database [4].

As a synthetic peptide intended to affect the structure or function of the body, MOTS-c meets the statutory definition of a drug under 21 U.S.C. § 321(g). Selling it without an approved NDA or an active IND exemption constitutes introducing an unapproved new drug into interstate commerce, which violates the Federal Food, Drug, and Cosmetic Act.

Compounding Pharmacy Status

The FDA's 503A and 503B bulk drug substance lists do not include MOTS-c. A substance must appear on the 503A "bulks list" for a traditional compounding pharmacy to lawfully prepare it for individual patients, or on the 503B list for an outsourcing facility to produce it in larger quantities without patient-specific prescriptions. MOTS-c appears on neither list [4]. Compounding pharmacies that dispense MOTS-c are operating in a legally contested space, and the FDA has the authority to take enforcement action.

Comparison to FDA-Cleared Peptides

For context, some peptides have received full FDA approval. Semaglutide (Ozempic, Wegovy) holds NDA 209637 and NDA 215256 respectively, supported by STEP-1 trial data (N=1,961) showing 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [5]. Tesamorelin (Egrifta) holds NDA 022505 for HIV-associated lipodystrophy. MOTS-c has no comparable regulatory anchor.

Safety Profile: What the Existing Data Show

There are no published Phase 1 human safety trials for MOTS-c. The safety information available comes from preclinical rodent studies, in vitro work, and endogenous physiology research. That is a narrow base for clinical decisions.

Preclinical Safety Signals

The Lee et al. 2015 paper reported no gross toxicity in mice receiving intraperitoneal MOTS-c at doses producing metabolic effects [1]. A 2019 study in Aging Cell examined MOTS-c in aged mouse models and found improvements in physical performance without reported organ toxicity at the doses used [6]. Preclinical no-observed-adverse-effect levels (NOAELs) have not been formally established using GLP-compliant toxicology studies, which are required before FDA IND submission.

Absence of Human Pharmacokinetic Data

No peer-reviewed study has characterized MOTS-c pharmacokinetics in humans: absorption after subcutaneous injection, volume of distribution, half-life, metabolic clearance, or dose-response relationships are all unknown in the clinical setting. The FDA's guidance on peptide drug development expects full PK/PD characterization in at least one species before first-in-human dosing, followed by a human PK study as part of Phase 1 [4].

Without published human PK data, clinicians cannot determine whether a given dose achieves physiologic or supraphysiologic concentrations, how long the peptide remains active, or whether accumulation occurs with repeated dosing.

Known and Theoretical Adverse Effects

Because no controlled human trials exist, adverse effect rates cannot be cited numerically. The theoretical risk profile is derived from mechanism:

• AMPK activation, MOTS-c's primary downstream effect, can lower blood glucose. In patients on insulin or sulfonylureas, additive hypoglycemia is plausible.
• Immune response to exogenous synthetic peptides, including anti-drug antibody formation, occurs with other approved peptides. The incidence for MOTS-c is unknown.
• Injection-site reactions are reported anecdotally in online forums but have not been systematically collected.
• Long-term effects on mitochondrial signaling pathways are unstudied at supraphysiologic doses.

The FDA's MedWatch system has no publicly searchable adverse event reports specifically attributed to MOTS-c as of January 2025, which reflects the absence of structured post-market surveillance rather than confirmed safety [4].

HealthRX Clinical Risk Framework: Evaluating Unapproved Peptides

When a patient or clinician asks whether an unapproved peptide like MOTS-c is appropriate to use, the HealthRX medical team applies a four-domain screen before any recommendation is made:

1. Regulatory standing. Does the peptide have an approved NDA, BLA, or active IND? If not, human use outside a clinical trial is off-label at best and unlawful interstate commerce at worst.
2. Human safety data. Has a Phase 1 trial established a maximum tolerated dose and characterized PK in humans? For MOTS-c, the answer is no.
3. Drug interaction risk. Does the mechanism interact with the patient's current medications? AMPK activation overlaps with metformin's mechanism, and the interaction magnitude in humans is unknown.
4. Supply chain integrity. Is the source a licensed pharmacy operating under USP 797 standards, or a research-chemical vendor with no pharmaceutical manufacturing oversight? Most MOTS-c sold online comes from the latter.

A peptide that fails any one of these four domains requires a documented informed-consent discussion before use. MOTS-c currently fails all four.

Regulatory Pathway: What Would Full FDA Approval Require?

Getting MOTS-c to FDA approval would follow the standard small-molecule or peptide NDA pathway, though the mitochondrial-DNA origin adds scientific complexity for IND reviewers.

Preclinical Package

The FDA's guidance for industry on nonclinical safety evaluation of peptide drugs requires GLP-compliant single-dose and repeat-dose toxicology studies in at least two species (one non-rodent), genotoxicity studies, reproductive toxicology if the indication includes populations of reproductive age, and formulation stability data [4]. None of these GLP studies have been publicly reported for MOTS-c.

Phase 1 Through Phase 3

A realistic development timeline for a metabolic peptide, from IND filing to NDA submission, runs eight to fourteen years based on historical averages for the metabolic disease category. The NEJM trial reporting the SUSTAIN-6 cardiovascular outcomes data for semaglutide, for instance, enrolled over 3,000 patients across 260 sites over two years for a single phase of development [7]. MOTS-c is at pre-IND stage.

Orphan Drug or Fast Track Designation

If a sponsor identified a rare disease target (a patient population under 200,000 in the United States), the FDA's Orphan Drug Act pathway could accelerate development with tax incentives and seven-year market exclusivity [4]. No orphan designation application for MOTS-c appears in the FDA's orphan-drug database. Fast Track designation is available for conditions without adequate therapy, but again requires an active IND.

What Clinicians Should Tell Patients Asking About MOTS-c

Patients frequently arrive at telehealth consultations having read about MOTS-c on longevity or biohacking platforms. A clear, factual conversation reduces both patient harm and prescriber liability.

Accurate Framing of Evidence

The existing science is genuinely interesting. Lee et al. 2015 placed MOTS-c on the map as a biologically real, endogenously produced peptide with measurable metabolic effects in rodents [1]. A 2021 paper in Communications Biology showed MOTS-c improves glucose regulation and mitochondrial function in aged non-human primate models [8]. Those findings justify further clinical development. They do not justify prescribing or self-injecting an uncharacterized compound outside a trial.

The American Diabetes Association's Standards of Care in Diabetes, updated annually, does not list MOTS-c as a therapeutic option at any tier [9]. The Endocrine Society's clinical practice guidelines on obesity pharmacotherapy, published in JCEM in 2022, similarly contain no reference to MOTS-c [10].

Liability and Informed Consent

Prescribing an unapproved drug without an active IND exposes a licensed clinician to FDA enforcement, state medical board action, and civil liability. The FDA's compliance policy guide on compounded drugs states clearly that compounded drugs are not FDA-approved and that prescribers share responsibility for ensuring a valid patient-specific medical need [4]. A telehealth clinician who prescribes MOTS-c from a vendor not on the 503A or 503B bulks list cannot point to FDA-approved labeling, cannot cite a published prescribing standard, and cannot cite human safety data in the event of an adverse outcome.

What to Offer Instead

Patients interested in the metabolic mechanisms MOTS-c targets (mitochondrial biogenesis, AMPK activation, insulin sensitivity) have access to compounds with established safety records. Metformin activates AMPK and has over 60 years of human use data; the FDA-approved label specifies starting doses of 500 mg twice daily with food for type 2 diabetes [11]. Tirzepatide (Mounjaro, NDA 215866) produces 22.5% mean weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539) and carries a complete FDA-approved label with prescribing guidance [12]. These are not the same as MOTS-c mechanistically, but they address overlapping metabolic goals with documented evidence.

Post-Market Surveillance and Future Monitoring

Because MOTS-c is not approved, the FDA's standard post-market surveillance infrastructure does not apply. No Risk Evaluation and Mitigation Strategy (REMS) exists. No pharmacovigilance database systematically captures adverse events. The only reporting mechanism is voluntary MedWatch submission by clinicians or patients who recognize a problem and take the initiative to report it.

What Would Change This Picture

A sponsor filing an IND with the FDA's Center for Drug Evaluation and Research (CDER), division of Metabolism and Endocrinology, would trigger formal regulatory review. That IND would require a completed pre-IND meeting, a submitted investigator brochure, and a Phase 1 protocol. If that IND were filed and a Phase 1 trial launched, MOTS-c would move from zero regulatory standing to conditional oversight. That transition has not occurred publicly as of January 2025.

The FDA's clinical holds database and ClinicalTrials.gov are the primary places to monitor for that change [3]. Clinicians with patients asking about MOTS-c should check those registries periodically rather than relying on vendor marketing claims.

The current plasma MOTS-c reference range in healthy adults, derived from the cross-sectional data available, is approximately 0.2 to 0.9 nmol/L, with levels roughly 40% lower in individuals over age 60 compared to those under 40 [2]. Whether exogenous MOTS-c can safely restore levels to a youthful range, and whether that restoration translates to clinical benefit, remains a question no human trial has answered.